AVEO
$2.95
Aveo Pharmaceuticals
($.02)
(.67%)
AVEO
Earnings Whisper ®
N/A
4th Quarter December 2017
Consensus:  ($0.03)
Revenue:  $1.00 Mil
Tuesday
Feb 6
7:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when AVEO reports earnings?
Beat
Meet
Miss

Where is AVEO's stock price going from here?
Up
Flat
Down
Stock chart of AVEO
Analysts
Summary of analysts' recommendations for AVEO
Score
Grade
Pivots
Resistance
$3.16
$3.09
$3.02

$2.96

Support
$2.89
$2.82
$2.75
Tweet
Growth
Description
AVEO Pharmaceuticals, Inc. is a biopharmaceutical company engaged in discovering, developing and commercializing novel cancer therapeutics. Its product candidates are targeted against important mechanisms known or believed to be involved in cancer. Tivozanib, the Company's lead product candidate, is a highly potent and selective oral inhibitor of the vascular endothelial growth factor, or VEGF, receptors 1, 2 and 3. In addition to tivozanib, AVEO Pharmaceuticals has a pipeline of monoclonal antibodies derived from Human Response Platform (HRP), a novel method of building preclinical models of human cancer, which are intended to more accurately represent cancer biology in patients. AV-299 is the Company's next product candidate which is an antibody that binds to hepatocyte growth factor, or HGF, thereby blocking its function. AVEO Pharmaceuticals, Inc. is based in Cambridge, Massachusetts.
Peers
CelgeneRegeneron PharmaceuticalsBioMarin PharmaceuticalVertex PharmaceuticalsJohnson & JohnsonEndo International plcInterCeptEli LillyZoetisBristol-Myers Squibb